UPDATE: Cowen and Company Downgrades Meridian Bioscience to Market Perform, Reiterates $21 PT on Tough Road Ahead

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

In a report published Tuesday, Cowen and Company analyst Shaun Rodriguez downgraded the rating on Meridian Bioscience (NASDAQ: VIVO) from Outperform to Market Perform, but reiterated the $21.00 price target.In the report, Cowen and Company noted, “Reaching 2013 revenue guidance would require a FH2 growth acceleration which we view as unlikely. Earnings guidance still appears achievable, but this is not likely enough of an offset. Accordingly, we see the bias to the downside and downgrade to Market Perform (from Outperform) with a $21 PT.”Meridian Bioscience closed on Monday at $22.86.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!